AuraCyt provides information on cell properties that is set to enhance analytical technology (PAT) to improve the pace and accuracy of single cell analysis.
“The AuraCyt brand name and our new website encapsulates and conveys the essence of Cytomos and its transformative technology,” Cytomos CEO David Rigterink said.
“We have and are attracting the brightest minds to help drive forward our exciting scientific, technological, business, marketing and commercial objectives.
“Our technology can provide intrinsic cell analysis data at speed to enable critically important, better-informed decision-making much earlier and can streamline product development to greatly reduce the cost and time taken to complete R&D programmes, technology transfer events and scaled manufacture.”
Cytomos’ platform can collect data that measures the properties of individual cells, for subsequent analysis and characterization. According to the company, the technology could ‘radically’ change the way that processes are monitored.
In addition, AuraCyt enables scientists to measure cells using a wide range of frequencies concurrently to build a picture of the cells in high dimensional space.
Therefore, the technology can sense deep within the cells as well as measure cell surface features, creating unique digital cell fingerprints.
These fingerprints can be used to both infer information about the cell or the cell population of interest and to predict cell behaviour in cell line development programmes and biomanufacturing events.
The company’s revamped website highlights the benefits of its technology for researchers, scientists and industrialists in both the biologics and cell and gene therapy sectors, Cytomos chief scientific officer Dr Lindsay Fraser said.
“Our fast and scalable platform closely monitors a broad range of individual cell features simultaneously, to provide label-free, unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications,” she added.
“AuraCyt can save and optimise batches, address pressing industry needs for smarter, less labour-intensive, and more automated processes capable of driving down biomanufacturing costs and realizing scale-out in the manufacture of personalised, regenerative medicines.”
